西妥昔单抗联合IMRT同步化疗治疗晚期鼻咽癌疗效观察.docVIP

西妥昔单抗联合IMRT同步化疗治疗晚期鼻咽癌疗效观察 　　【摘要】 目的 观察西妥昔单抗联合调强适形放疗（IMRT）同步化疗治疗晚期鼻咽癌的临床疗效。方法 64例晚期鼻咽癌患者， 根据治疗方法差异分为对照组与观察组， 每组32例。对照组患者给予IMRT同步顺铂化疗治疗， 观察组患者给予西妥昔单抗联合IMRT同步化疗治疗， 观察两组患者的临床治疗效果， 并统计两组患者治疗过程中的不良反应发生情况。结果 观察组患者治疗显效17例， 有效13例， 无效2例， 总有效率为93.75%（30/32）；对照组患者治疗显效10例， 有效14例， 无效8例， 总有效率为75.00%（24/32）；观察?M总有效率高于对照组， 差异有统计学意义（χ2=4.2667， P0.05）。观察组不良反应发生率为9.38%（3/32）， 对照组不良反应发生率为34.38%（11/32）， 比较差异有统计学意义（χ2=5.8514， P0.05）。结论 应用西妥昔单抗联合IMRT同步化疗治疗晚期鼻咽癌的临床疗效显著， 不良反应发生情况较少， 安全性较高， 可在临床进一步推广应用。 　　【关键词】 西妥昔单抗；调强适形放疗；同步化疗；晚期鼻咽癌 　　DOI：10.14163/j.cnki.11-5547/r.2018.09.054 　　【Abstract】 Objective To observe the clinical efficacy of cetuximab combined with intensity modulated radiation therapy （IMRT） synchronous chemotherapy in the treatment of advanced nasopharyngeal carcinoma. Methods A total of 64 advanced nasopharyngeal carcinoma patients were divided by different treatment methods into control group and observation group， with 32 cases in each group. The control group was treated with IMRT synchronous cisplatin chemotherapy， and the observation group was treated with cetuximab combined with IMRT synchronous chemotherapy. The clinical effects of the two groups were observed， and the incidence of adverse reactions in the two groups were calculated. Results The observation group had 17 excellent cases， 13 effective cases and 2 ineffective cases， with total effective rate as 93.75% （30/32）， which were 10 cases， 14 cases， 8 cases and 75.00% （24/32） in the control group. The observation group had higher total effective rate than the control group， and the difference was statistically significant （χ2=4.2667， P0.05）. The observation group had incidence of adverse reactions as 9.38% （3/32）， which was 34.38% （11/32） in the control group， and the difference was statistically significant （χ2=5.8514， P0.05）. Conclusion Combination of cetuximab and IMRT synchronous chemotherapy shows remarkable clinical efficacy in the treatment of advanced nasopharyngeal carcinoma with less adverse reactions